Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) and Exosome Sciences Announce Clinical Collaboration with Boston
University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former
NFL Players
SAN DIEGO, PRINCETON, N.J. and BOSTON - September 26, 2014
(Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) and its diagnostic
subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical
collaboration with the Boston University (BU) CTE Center has been established
to advance a blood-based diagnostic candidate that could identify Chronic
Traumatic Encephalopathy (CTE) in living individuals.
CTE
is a progressive neurodegenerative disorder that has been found at autopsy in
former National Football League (NFL) players. At present, CTE can only be
diagnosed through postmortem autopsy. The BU CTE Center has been a leading CTE
research center since the disease was first defined.
Aethlon
Medical develops targeted therapeutic devices to address infectious disease,
cancer and neurodegenerative disorders. ESI (Aethlon subsidiary) develops
exosome-based solutions to diagnose and monitor cancer and neurodegenerative
disorders. Earlier this year, Aethlon disclosed that ESI researchers had
successfully isolated exosome-based biomarkers transporting tau protein across
the blood-brain barrier and into the circulatory system. The hallmark of CTE is
an excess of accumulation of tau in the brain.
In
the study, ESI researchers are evaluating and defining exosome and exosomal tau
populations in blood samples collected from participants enrolled in the DETECT
(Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests)
study, under the direction of Dr. Robert Stern, Director of Clinical Research
at the BU CTE Center.
The
DETECT study is the first research project on CTE ever funded by the National
Institutes of Health (NIH), with support from the National Institute of
Neurologic Diseases and Stroke (NINDS), the National Institute on Aging (NIA),
and the National Institute of Child Health and Human Development (NICHD). The
ultimate goal of the study is to develop methods, including blood-based tests,
that could diagnose CTE during life. The study has enrolled former NFL players
(ages 40-69) and same-age "control" athletes who played non-contact
sports.
"Our
colleagues at the CTE Center are premier thought leaders in the CTE field and
have been instrumental in changing how the NFL and other high-risk sports
respond to head trauma," stated Aethlon Medical CEO Jim Joyce, who also
serves as Executive Chairman of ESI. "We are truly grateful for the
opportunity to establish a blood-based test that could identify CTE in living individuals."
About CTE
Chronic
Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the
brain found in athletes (and others) with a history of repetitive brain trauma,
including symptomatic concussions as well as asymptomatic subconcussive hits to
the head. CTE affects boxers, football players and other athletes who have a
history of repetitive brain trauma. Repetitive trauma triggers a progressive
degeneration of the brain tissue, including the build-up of an abnormal protein
called tau. Symptoms of the neurodegeneration can develop months, years, or
even decades after the last brain trauma or end of active athletic involvement.
The brain degeneration is associated with memory loss, confusion, impaired
judgment, impulse control problems, aggression, depression, and, eventually,
progressive dementia.
About The CTE Center
The
CTE Center is part of the Boston University Alzheimer's Disease Center (BU
ADC), established in 1996 as one of 29 centers in the US funded by the National
Institutes of Health to advance research on Alzheimer's disease and related
conditions. In collaboration with other NIH-funded ADC's and the non-profit
Sports Legacy Institute, CTE Center conducts high-impact, innovative research
on CTE, including its neuropathology and pathogenesis, clinical presentation,
genetics and other risk factors, biomarkers, methods of detection during life,
and methods of prevention and treatment. Additional information can be found
online at: www.bu.edu/cte
About Exosome Sciences, Inc.
Exosome
Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc.,
develops exosome-based solutions to improve identification and monitoring of
acute and chronic conditions. Our candidate products are focused toward diagnostic
advancements in the fields of oncology, infectious disease and brain injury.
Exosomes represent an optimal diagnostic target as diseased or injured cells
release these particles into body fluids such as urine, blood, saliva and
cerebrospinal fluid where they can be accessed for analysis. Our exosome-based
assays unlock the ability to identify proteomic and genomic alterations
underlying a wide-range of pathologies, thus allowing for the introduction of
novel non-invasive "liquid biopsies". Additional information can be
found online at www.ExosomeSciences.com
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease, cancer and neurodegenerative disorders. The company's lead
product is the Aethlon Hemopurifier®, a first-in-class device that selectively
targets the rapid elimination of circulating viruses and tumor-secreted
exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority
owned subsidiary that is advancing exosome-based products to diagnose and
monitor cancer, infectious disease and neurological disorders. Additional
information can be found online at www.AethlonMedical.com.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Jim
Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer : Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories
24/7 –biotech, mining stocks, oil and gas stocks and more...
